ExeGi Pharma Revenue and Competitors
Estimated Revenue & Valuation
- ExeGi Pharma's estimated annual revenue is currently $4.3M per year.
- ExeGi Pharma's estimated revenue per employee is $155,000
Employee Data
- ExeGi Pharma has 28 Employees.
- ExeGi Pharma grew their employee count by 8% last year.
ExeGi Pharma's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | VP, Animal Health | Reveal Email/Phone |
4 | Director Project Management | Reveal Email/Phone |
5 | Marketing Director | Reveal Email/Phone |
6 | Director | Reveal Email/Phone |
7 | Customer Service Manager | Reveal Email/Phone |
8 | Operations Manager | Reveal Email/Phone |
9 | Marketing Analyst | Reveal Email/Phone |
ExeGi Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is ExeGi Pharma?
ExeGi Pharma is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. Our team leverages the field of microbiome science to deliver novel, clinically supported, live biotherapeutic and probiotic treatments for a variety of unmet medical needs for both humans and veterinary applications. Makers of Visbiome and Visbiome Vet high potency probiotics.
keywords:N/AN/A
Total Funding
28
Number of Employees
$4.3M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.8M | 28 | -10% | N/A |
#2 | $2M | 28 | 0% | N/A |
#3 | $5.3M | 28 | -3% | N/A |
#4 | $4.3M | 28 | -3% | N/A |
#5 | $2.7M | 28 | -20% | N/A |